Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 8, 2025Journal of Antimicrobial Chemotherapy

Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChih‐Cheng LaiCLChia‐Ying LiuKHKang Huang

Discussion

Loading...

Member takes

Overview

Observational analysis reveals high non-susceptibility rates in carbapenem-resistant Enterobacterales, suggesting alternative antibiotics are necessary.

Key Points

  • In vitro susceptibility rates for aztreonam–avibactam and colistin exceeded 86%, while amikacin and meropenem–vaborbactam showed poor performance.
  • Non-susceptibility rates for amikacin and meropenem–vaborbactam were 78.7% and 94.8%, regardless of region, infection source or species.
  • The prevalence of blaCTX-M-15 was closely correlated with amikacin non-susceptibility rates across Klebsiella pneumoniae and Escherichia coli.
  • High levels of ceftazidime–avibactam-resistant Enterobacterales necessitate investigations for effective antibiotic treatments.

Cite This Study

Lai et al. (2025) studied this question.

synapsesocial.com/papers/68e6bc5f38ca8e474d549d3ehttps://doi.org/10.1093/jac/dkaf375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Epidemiology of Carbapenem-Resistant P. aeruginosa and Enterobacterales Isolates from Clinical Infections and Their Susceptibility to Ceftazidime–Avibactam2025
  2. 2IN VITRO SUSCEPTIBILITY COMPARISON OF AZTREONAM ALONG WITH CEFTAZIDIME-AVIBACTAM SYNERGY TESTING METHODS AND AZTREONAMAVIBACTAM AGAINST CARBAPENEM RESISTANT ORGANISMS IN ISOLATES OBTAINED FROM CANCER PATIENTS2025
  3. 3Molecular Epidemiology of Infections Caused by Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> and Enterobacterales and Susceptibility of Isolates to Ceftazidime-Avibactam2025
  4. 4Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025
  5. 5In Vitro Activity of Cefiderocol and Aztreonam/Avibactam Against Gram-Negative Non-Fermenting Bacteria: A New Strategy Against Highly Antibiotic-Resistant Infectious Agents2025 · 4 citations